Skip to content

GREEN VISION BIOTECHNOLOGY CORP.: 10-Q filed 2016-12-20

What GREEN VISION BIOTECHNOLOGY CORP. reported in its quarterly report filed 2016-12-20 (fiscal Q3 2017): 10 published measures, 27 facts as tagged in accession 0001640334-16-002264.

This filing

Form
10-Q (quarterly report)
Filed
2016-12-20
Fiscal period
fiscal Q3 2017
Accession
0001640334-16-002264 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GREEN VISION BIOTECHNOLOGY CORP. filings.

Reported measures

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-10-3189,583USD
At 2016-01-3137,035USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-10-31-89,583USD
At 2016-01-31-37,035USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-01-31175USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-08-01 to 2016-10-31-35,593USD92
2016-02-01 to 2016-10-31-52,548USD274
2015-08-01 to 2015-10-31-5,918USD92
2015-02-01 to 2015-10-31-15,493USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-10-31-133,511USD
At 2016-01-31-80,963USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-10-3189,583USD
At 2016-01-3137,035USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-08-01 to 2016-10-3135,593USD92
2016-02-01 to 2016-10-3152,548USD274
2015-08-01 to 2015-10-315,918USD92
2015-02-01 to 2015-10-3115,493USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-10-3160,790,000shares
At 2016-01-3160,790,000shares

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-08-01 to 2016-10-31-35,593USD92
2016-02-01 to 2016-10-31-52,548USD274
2015-08-01 to 2015-10-31-5,918USD92
2015-02-01 to 2015-10-31-15,493USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-08-01 to 2016-10-3135,593USD92
2016-02-01 to 2016-10-3152,548USD274
2015-08-01 to 2015-10-315,918USD92
2015-02-01 to 2015-10-3115,493USD273

Inspect the source

Entity
GREEN VISION BIOTECHNOLOGY CORP. / CIK 0001571804
Captured
SEC response SHA-256
f900c79f6de11454e9e92e93c55c93d276ffa598a95106526ff88cb826780ecf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001571804.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))